Onsdag 25 Juni | 02:09:52 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-02-13 08:30 Bokslutskommuniké 2025
2025-11-05 08:00 Kvartalsrapport 2025-Q3
2025-08-20 08:00 Kvartalsrapport 2025-Q2
2025-05-15 - X-dag ordinarie utdelning SENZA 0.00 SEK
2025-05-14 - Årsstämma
2025-05-14 - Kvartalsrapport 2025-Q1
2025-02-13 - Bokslutskommuniké 2024
2024-11-08 - Kvartalsrapport 2024-Q3
2024-08-22 - Kvartalsrapport 2024-Q2
2024-05-16 - X-dag ordinarie utdelning SENZA 0.00 SEK
2024-05-15 - Årsstämma
2024-05-15 - Kvartalsrapport 2024-Q1
2024-02-14 - Bokslutskommuniké 2023
2023-08-24 - Kvartalsrapport 2023-Q2
2023-05-05 - X-dag ordinarie utdelning SENZA 0.00 SEK
2023-05-04 - Årsstämma
2023-02-16 - Bokslutskommuniké 2022
2022-08-18 - Kvartalsrapport 2022-Q2
2022-05-06 - X-dag ordinarie utdelning SENZA 0.00 SEK
2022-05-05 - Årsstämma
2022-02-11 - Bokslutskommuniké 2021
2021-08-19 - Kvartalsrapport 2021-Q2
2021-05-06 - X-dag ordinarie utdelning SENZA 0.00 SEK
2021-05-05 - Årsstämma
2021-02-18 - Bokslutskommuniké 2020
2020-08-20 - Kvartalsrapport 2020-Q2
2020-05-11 - X-dag ordinarie utdelning SENZA 0.00 SEK
2020-05-08 - Årsstämma
2020-02-13 - Bokslutskommuniké 2019
2019-12-18 - Extra Bolagsstämma 2019
2019-08-22 - Kvartalsrapport 2019-Q2
2019-05-16 - X-dag ordinarie utdelning SENZA 0.00 SEK
2019-05-15 - Årsstämma
2019-02-14 - Bokslutskommuniké 2018
2018-08-22 - Kvartalsrapport 2018-Q2
2018-05-09 - X-dag ordinarie utdelning SENZA 0.00 SEK
2018-05-08 - Årsstämma
2018-02-14 - Bokslutskommuniké 2017

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Senzagen är verksamt inom medicinteknik. Bolaget utvecklar och genomför genomiska in vitro-tester, vilket innebär att olika kemikaliers toxikologiska förmåga inte testas på djur utan istället i provrör. Bolaget har utvecklat en teknologisk plattform som används för att studera substansers påverkan producerat av aktörer inom läkemedel, kosmetika- och kemikalieindustrin. Forskning och utveckling sker från huvudkontoret i Lund.
2025-06-24 08:30:00

SenzaGen has been awarded a new grant worth 1.5 MSEK from the Research Institute for Fragrance Materials (RIFM), a leading international research institute in fragrance safety. The assignment involves evaluating the GARD®skin Dose-Response assay to determine the dose levels at which fragrance ingredients may cause skin allergies upon when exposure to sunlight, a phenomenon known as photosensitization. The testing will begin in Q2 2025 and continue throughout the year.

The new assignment builds on the long-standing collaboration between the parties and aims to further develop the GARD® technology in the area of photosensitization. The ambition is to identify substances that can trigger allergic skin reactions when exposed to sunlight (photoallergens) and distinguish them from substances that cause temporary irritation (photoirritants). This is a scientifically challenging area with no validated methods currently available. The project holds strategic importance for the company.

“Together with RIFM, we look forward to driving innovation in a field where the need for alternative methods is high. Our GARD® technology has the potential to make important contributions also in this area, and we are very pleased to deepen our collaboration with RIFM through this exciting project,” says Peter Nählstedt, CEO and President of SenzaGen.

RIFM is an international research institute responsible for safety assessments of fragrance ingredients used in consumer products worldwide. Their evaluations help companies understand and manage the safe use of fragrance materials.

“Building on our previous work, we aim to better understand how the GARD® method can be applied to identify photoallergens and differentiate them from photoirritants – a scientifically and industrially relevant challenge we hope to find a solution for,” says Gretchen Ritacco, MS, Principal Scientist, Dermatotoxicology at RIFM.

About RIFM
Established in 1966, the Research Institute for Fragrance Materials (RIFM) generates, analyzes, evaluates, and distributes data to provide a scientific basis for the safe use of fragrances. RIFM has compiled the most comprehensive, worldwide source of toxicology data, literature, and general information on fragrance and flavor raw materials. RIFM’s Fragrance Ingredient Safety Assessment program draws from its comprehensive database of over 80,000 references and approximately 200,000 human health and environmental studies.

RIFM assesses the safety of fragrance ingredients by the most current, internationally accepted guidelines—and has done so since its founding. The Expert Panel for Fragrance Safety, an independent, international team of researchers and academics with no ties to the fragrance industry, reviews all of RIFM’s work before RIFM submits it for peer-reviewed publication in a reputable scientific journal. RIFM makes all of its published, peer-reviewed work—current and historical—available for free at fragrancematerialsafetyresource.elsevier.com.

Contacts

Peter Nählstedt, President and CEO, SenzaGen AB
Email: peter.nahlstedt@senzagen.com | Mobile: 0700-23 44 31

RIFM
Gary Sullivan, Marketing & Communications Manager, RIFM
Email: gsullivan@rifm.org